Aspira Women’s Health (NASDAQ:AWH) Upgraded to Hold by StockNews.com

Aspira Women’s Health (NASDAQ:AWH) was upgraded by investment analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Wednesday.

Separately, Alliance Global Partners reduced their price target on shares of Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating on the stock in a research report on Wednesday, August 14th.

Aspira Women’s Health Price Performance

AWH opened at $0.86 on Wednesday. The company has a market capitalization of $10.73 million, a P/E ratio of -0.59 and a beta of 1.48. The firm’s fifty day moving average price is $1.17 and its two-hundred day moving average price is $2.18. Aspira Women’s Health has a fifty-two week low of $0.81 and a fifty-two week high of $6.10.

Aspira Women’s Health (NASDAQ:AWH) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. The company had revenue of $2.42 million for the quarter, compared to the consensus estimate of $2.60 million. During the same period in the previous year, the business posted ($0.28) earnings per share. On average, equities research analysts expect that Aspira Women’s Health will post -1.26 EPS for the current fiscal year.

Institutional Investors Weigh In On Aspira Women’s Health

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. grew its position in Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% in the second quarter, according to its most recent filing with the SEC. The fund owned 236,396 shares of the company’s stock after acquiring an additional 111,022 shares during the period. B. Riley Wealth Advisors Inc. owned 1.90% of Aspira Women’s Health worth $352,000 as of its most recent filing with the SEC. Institutional investors own 12.19% of the company’s stock.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.